{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:25:27Z","timestamp":1794489927690,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome with specific inhibitors (PI). The resulting interference with protein degradation is particularly toxic to MM cells as they typically accumulate large amounts of toxic proteins. However, MM cells often acquire resistance to PIs through aberrant expression or mutations of proteasome subunits such as PSMB5, resulting in disease recurrence and further treatment failure. Here we propose CuET\u2014a proteasome-like inhibitor agent that is spontaneously formed in-vivo and in-vitro from the approved alcohol-abuse drug disulfiram (DSF), as a readily available treatment effective against diverse resistant forms of MM. We show that CuET efficiently kills also resistant MM cells adapted to proliferate under exposure to common anti-myeloma drugs such as bortezomib and carfilzomib used as the first-line therapy, as well as to other experimental drugs targeting protein degradation upstream of the proteasome. Furthermore, CuET can overcome also the adaptation mechanism based on reduced proteasome load, another clinically relevant form of treatment resistance. Data obtained from experimental treatment-resistant cellular models of human MM are further corroborated using rather unique advanced cytotoxicity experiments on myeloma and normal blood cells obtained from fresh patient biopsies including newly diagnosed as well as relapsed and treatment-resistant MM. Overall our findings suggest that disulfiram repurposing particularly if combined with copper supplementation may offer a promising and readily available treatment option for patients suffering from relapsed and\/or therapy-resistant multiple myeloma.<\/jats:p>","DOI":"10.1038\/s41419-022-04651-w","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T13:26:14Z","timestamp":1646400374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0141-0469","authenticated-orcid":false,"given":"Katarina","family":"Chroma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6004-3609","authenticated-orcid":false,"given":"Zdenek","family":"Skrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Gursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Bacovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-007X","authenticated-orcid":false,"given":"Pavel","family":"Moudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5233-1504","authenticated-orcid":false,"given":"Tereza","family":"Buchtova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2321-0348","authenticated-orcid":false,"given":"Martin","family":"Mistrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2013-7525","authenticated-orcid":false,"given":"Jiri","family":"Bartek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"4651_CR1","first-page":"65","volume":"3","author":"KC Anderson","year":"2004","unstructured":"Anderson KC. Bortezomib therapy for myeloma. Curr Hematol Rep. 2004;3:65.","journal-title":"Curr Hematol Rep."},{"key":"4651_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","volume":"50","author":"RT Greenlee","year":"2000","unstructured":"Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7\u201333.","journal-title":"CA Cancer J Clin."},{"key":"4651_CR3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","volume":"35","author":"K Allmeroth","year":"2021","unstructured":"Allmeroth K, Horn M, Kroef V, Miethe S, M\u00fcller R-U, Denzel MS. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia 2021;35:887\u201392.","journal-title":"Leukemia"},{"key":"4651_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","volume":"33","author":"S Barrio","year":"2019","unstructured":"Barrio S, St\u00fchmer T, Da-Vi\u00e1 M, Barrio-Garcia C, Lehners N, Besse A, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 2019;33:447\u201356.","journal-title":"Leukemia"},{"key":"4651_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nchembio.2326","volume":"13","author":"J Li","year":"2017","unstructured":"Li J, Yakushi T, Parlati F, Mackinnon AL, Perez C, Ma Y, et al. Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat Chem Biol. 2017;13:486\u201393.","journal-title":"Nat Chem Biol"},{"key":"4651_CR6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/nm.2536","volume":"17","author":"P D\u2019Arcy","year":"2011","unstructured":"D\u2019Arcy P, Brnjic S, Olofsson MH, Frykn\u00e4s M, Lindsten K, De Cesare M, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011;17:1636\u201340.","journal-title":"Nat Med."},{"key":"4651_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ccr.2013.11.001","volume":"24","author":"RK Anchoori","year":"2013","unstructured":"Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, et al. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13\/ADRM1 as a therapy for cancer. Cancer Cell. 2013;24:791\u2013805.","journal-title":"Cancer Cell."},{"key":"4651_CR8","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/leu.2016.97","volume":"30","author":"Y Song","year":"2016","unstructured":"Song Y, Ray A, Li S, Das DS, Tai YT, Carrasco RD, et al. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma. Leukemia 2016;30:1877\u201386.","journal-title":"Leukemia"},{"key":"4651_CR9","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1038\/onc.2017.172","volume":"36","author":"Y Song","year":"2017","unstructured":"Song Y, Li S, Ray A, Das DS, Qi J, Samur MK, et al. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene 2017;36:5631\u20138.","journal-title":"Oncogene"},{"key":"4651_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian Z, D\u2019Arcy P, Wang X, Ray A, Tai Y-T, Hu Y, et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 2014;123:706\u201316.","journal-title":"Blood"},{"key":"4651_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nm.4474","volume":"24","author":"ML Hyer","year":"2018","unstructured":"Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018;24:186\u201393.","journal-title":"Nat Med"},{"key":"4651_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2015.10.002","volume":"28","author":"DJ Anderson","year":"2015","unstructured":"Anderson DJ, Le Moigne R, Djakovic S, Kumar B, Rice J, Wong S, et al. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell. 2015;28:653\u201365.","journal-title":"Cancer Cell"},{"key":"4651_CR13","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1182\/blood-2018-06-859686","volume":"133","author":"J Zhuang","year":"2019","unstructured":"Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, et al. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood 2019;133:1572\u201384.","journal-title":"Blood"},{"key":"4651_CR14","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1158\/1535-7163.MCT-17-0233","volume":"16","author":"R Le Moigne","year":"2017","unstructured":"Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, et al. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Mol Cancer Ther. 2017;16:2375\u201386.","journal-title":"Mol Cancer Ther"},{"key":"4651_CR15","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1182\/blood-2012-05-426924","volume":"120","author":"DI Lichter","year":"2012","unstructured":"Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, et al. Sequence analysis of \u03b2-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 2012;120:4513\u20136.","journal-title":"Blood"},{"key":"4651_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.leukres.2005.06.014","volume":"30","author":"M Politou","year":"2006","unstructured":"Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res. 2006;30:240\u20131.","journal-title":"Leuk Res"},{"key":"4651_CR17","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","volume":"32","author":"J Corre","year":"2018","unstructured":"Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia 2018;32:2636\u201347.","journal-title":"Leukemia"},{"key":"4651_CR18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","volume":"4","author":"B Ziccheddu","year":"2020","unstructured":"Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH, et al. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv. 2020;4:830\u201344.","journal-title":"Blood Adv"},{"key":"4651_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24:289\u2013304.","journal-title":"Cancer Cell"},{"key":"4651_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/sj.emboj.7601009","volume":"25","author":"S Cenci","year":"2006","unstructured":"Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A, et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006;25:1104\u201313.","journal-title":"EMBO J"},{"key":"4651_CR21","doi-asserted-by":"crossref","unstructured":"Ling SCW, Lau EKK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. 1. 2012;97:64\u201372.","DOI":"10.3324\/haematol.2011.043331"},{"key":"4651_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-020-0216-1","volume":"9","author":"M Zang","year":"2020","unstructured":"Zang M, Guo J, Liu L, Jin F, Feng X, An G, et al. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis 2020;9:1\u201313.","journal-title":"Oncogenesis"},{"key":"4651_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/bloodadvances.2018019851","volume":"3","author":"X-Q Qin","year":"2019","unstructured":"Qin X-Q, An G, Li Z-J, Liu L-T, Xu Y, Yang L-H, et al. Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. Blood Adv. 2019;3:751\u201360.","journal-title":"Blood Adv"},{"key":"4651_CR24","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783\u201392.","journal-title":"Cancer Res"},{"key":"4651_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/leu.2016.211","volume":"31","author":"B Paiva","year":"2017","unstructured":"Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, et al. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia 2017;31:382\u201392.","journal-title":"Leukemia"},{"key":"4651_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","volume":"121","author":"A Chaidos","year":"2013","unstructured":"Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 2013;121:318\u201328.","journal-title":"Blood"},{"key":"4651_CR27","doi-asserted-by":"publisher","first-page":"110048","DOI":"10.1016\/j.biopha.2020.110048","volume":"126","author":"Y Xu","year":"2020","unstructured":"Xu Y, Zhou Q, Feng X, Dai Y, Jiang Y, Jiang W, et al. Disulfiram\/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways. Biomed Pharmacother. 2020;126:110048.","journal-title":"Biomed Pharmacother"},{"key":"4651_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04078-9","volume":"12","author":"S Meier","year":"2021","unstructured":"Meier S, Cantilena S, Niklison Chirou MV, Anderson J, Hargrave D, Salomoni P, et al. Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation. Cell Death Dis. 2021;12:1\u201312.","journal-title":"Cell Death Dis"},{"key":"4651_CR29","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","volume":"66","author":"D Chen","year":"2006","unstructured":"Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66:10425\u201333.","journal-title":"Cancer Res"},{"key":"4651_CR30","doi-asserted-by":"publisher","first-page":"e0236119","DOI":"10.1371\/journal.pone.0236119","volume":"15","author":"H Yoshino","year":"2020","unstructured":"Yoshino H, Yamada Y, Enokida H, Osako Y, Tsuruda M, Kuroshima K, et al. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. PLoS ONE. 2020;15:e0236119.","journal-title":"PLoS ONE"},{"key":"4651_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature25016","volume":"552","author":"Z Skrott","year":"2017","unstructured":"Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 2017;552:194\u20139.","journal-title":"Nature"},{"key":"4651_CR32","doi-asserted-by":"crossref","unstructured":"Majera D, Skrott Z, Chroma K, Merchut-Maya JM, Mistrik M, Bartek J. Targeting the NPL4 Adaptor of p97\/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway. Cells. 2020;18:9.","DOI":"10.3390\/cells9020469"},{"key":"4651_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/35087056","volume":"3","author":"RM Dai","year":"2001","unstructured":"Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol. 2001;3:740\u20134.","journal-title":"Nat Cell Biol"},{"key":"4651_CR34","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907\u201316.","journal-title":"Blood"},{"key":"4651_CR35","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/leu.2009.173","volume":"23","author":"JJ Shah","year":"2009","unstructured":"Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009;23:1964\u201379.","journal-title":"Leukemia"},{"key":"4651_CR36","doi-asserted-by":"publisher","first-page":"6711","DOI":"10.1038\/s41388-019-0915-2","volume":"38","author":"Z Skrott","year":"2019","unstructured":"Skrott Z, Majera D, Gursky J, Buchtova T, Hajduch M, Mistrik M, et al. Disulfiram\u2019s anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase. Oncogene 2019;38:6711\u201322.","journal-title":"Oncogene"},{"key":"4651_CR37","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1189\/jlb.1011497","volume":"92","author":"S Cenci","year":"2012","unstructured":"Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, et al. Pivotal Advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012;92:921\u201331.","journal-title":"J Leukoc Biol"},{"key":"4651_CR38","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/leu.2009.8","volume":"23","author":"T R\u00fcckrich","year":"2009","unstructured":"R\u00fcckrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, et al. Characterization of the ubiquitin\u2013proteasome system in bortezomib-adapted cells. Leukemia 2009;23:1098\u2013105.","journal-title":"Leukemia"},{"key":"4651_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","volume":"121","author":"FP O\u2019Connell","year":"2004","unstructured":"O\u2019Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121:254\u201363.","journal-title":"Am J Clin Pathol"},{"key":"4651_CR40","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","volume":"123","author":"I Frigyesi","year":"2014","unstructured":"Frigyesi I, Adolfsson J, Ali M, Christophersen MK, Johnsson E, Turesson I, et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood 2014;123:1336\u201340.","journal-title":"Blood"},{"key":"4651_CR41","doi-asserted-by":"crossref","unstructured":"Soh KT, Tario JD, Hahn T, Hillengass J, McCarthy PL, Wallace PK CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Cytometry Part B, Clinical Cytometry [Internet]. 2020 Oct 6 [cited 2022 Jan 21]; Available from: https:\/\/www.meta.org\/papers\/cd319-slamf7-an-alternative-marker-for-detecting\/33017079.","DOI":"10.1002\/cyto.b.21961"},{"key":"4651_CR42","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","volume":"120","author":"JA Zonder","year":"2012","unstructured":"Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120:552\u20139.","journal-title":"Blood"},{"key":"4651_CR43","doi-asserted-by":"crossref","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH. Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12020407"},{"key":"4651_CR44","doi-asserted-by":"crossref","unstructured":"Meraz-Torres F, Pl\u00f6ger S, Garbe C, Niessner H, Sinnberg T. Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma-Old Myth or New Logos? Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12123538"},{"key":"4651_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0009-2797(00)00225-8","volume":"130\u2013132","author":"JJ Lipsky","year":"2001","unstructured":"Lipsky JJ, Shen ML, Naylor S. In vivo inhibition of aldehyde dehydrogenase by disulfiram. Chem-Biol Interact. 2001;130\u2013132:93\u2013102.","journal-title":"Chem-Biol Interact"},{"key":"4651_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20359-x","volume":"12","author":"M Pan","year":"2021","unstructured":"Pan M, Zheng Q, Yu Y, Ai H, Xie Y, Zeng X, et al. Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative. Nat Commun. 2021;12:121.","journal-title":"Nat Commun"},{"key":"4651_CR47","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/ijc.27482","volume":"131","author":"C Conticello","year":"2012","unstructured":"Conticello C, Martinetti D, Adamo L, Buccheri S, Giuffrida R, Parrinello N, et al. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int J Cancer. 2012;131:2197\u2013203.","journal-title":"Int J Cancer"},{"key":"4651_CR48","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.bbadis.2019.04.003","volume":"1865","author":"D Br\u00fcnnert","year":"2019","unstructured":"Br\u00fcnnert D, Kraus M, St\u00fchmer T, Kirner S, Heiden R, Goyal P, et al. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. Biochimica et Biophysica Acta (BBA) - Mol Basis Dis. 2019;1865:1666\u201376.","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol Basis Dis"},{"key":"4651_CR49","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3389\/fonc.2019.01530","volume":"9","author":"B Borjan","year":"2019","unstructured":"Borjan B, Kern J, Steiner N, Gunsilius E, Wolf D, Untergasser G. Spliced XBP1 levels determine sensitivity of multiple myeloma cells to proteasome inhibitor bortezomib independent of the unfolded protein response mediator GRP78. Front Oncol. 2019;9:1530.","journal-title":"Front Oncol"},{"key":"4651_CR50","doi-asserted-by":"publisher","first-page":"21588","DOI":"10.1073\/pnas.2001323117","volume":"117","author":"Z Sha","year":"2020","unstructured":"Sha Z, Goldberg AL. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis. PNAS 2020;117:21588\u201397.","journal-title":"PNAS"},{"key":"4651_CR51","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/onc.2016.392","volume":"36","author":"K Chroma","year":"2017","unstructured":"Chroma K, Mistrik M, Moudry P, Gursky J, Liptay M, Strauss R, et al. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. Oncogene 2017;36:2405\u201322.","journal-title":"Oncogene"},{"key":"4651_CR52","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.3390\/cancers13153755","volume":"13","author":"L Dutrieux","year":"2021","unstructured":"Dutrieux L, Lin Y-L, Lutzmann M, Rodriguez R, Cogn\u00e9 M, Pasero P, et al. Transcription\/replication conflicts in tumorigenesis and their potential role as novel therapeutic targets in multiple myeloma. Cancers 2021;13:3755.","journal-title":"Cancers"},{"key":"4651_CR53","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","volume":"5","author":"F Cottini","year":"2015","unstructured":"Cottini F, Hideshima T, Suzuki R, Tai Y-T, Bianchini G, Richardson PG, et al. Synthetic lethal approaches exploiting DNA damage in aggressive myeloma. Cancer Disco. 2015;5:972\u201387.","journal-title":"Cancer Disco"},{"key":"4651_CR54","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/leu.2011.94","volume":"25","author":"DK Walters","year":"2011","unstructured":"Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, et al. Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia 2011;25:1344\u201353.","journal-title":"Leukemia"},{"key":"4651_CR55","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3324\/haematol.2018.215210","volume":"105","author":"OA Botrugno","year":"2020","unstructured":"Botrugno OA, Bianchessi S, Zambroni D, Frenquelli M, Belloni D, Bongiovanni L, et al. ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies. Haematologica 2020;105:2440\u20137.","journal-title":"Haematologica"},{"key":"4651_CR56","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","volume":"26","author":"J Bartek","year":"2007","unstructured":"Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007;26:7773\u20139.","journal-title":"Oncogene"},{"key":"4651_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-176","volume":"9","author":"S Markovina","year":"2010","unstructured":"Markovina S, Callander NS, O\u2019Connor SL, Xu G, Shi Y, Leith CP, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-\u03baB activity in myeloma cells. Mol Cancer. 2010;9:176.","journal-title":"Mol Cancer."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04651-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:37:56Z","timestamp":1700307476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04651-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["4651"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-04651-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study has been approved by the Ethics Committee of the Faculty hospital and Medical faculty of the University of Palacky in Olomouc, Czech Republic. Reference number: 94\/21.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"203"}}